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Let-7, a gene firstly known to control the timing of Caenorhabditis elegans larval development does not code for a
protein but instead produces small non-coding RNAs, microRNAs. Higher animals have multiple isoforms of
mature let-7 microRNAs. Mature let-7 family members share the same “seed sequence” and distinct from each
other slightly by ‘non-seed’ sequence region. Let-7 has emerged as a central regulator of systemic energy
homeostasis and it displays remarkable plasticity in metabolic responses to nutrients availability and physiological
activities. In this review, we discuss recent studies highlighting post-transcriptional mechanisms that govern
metabolic reprogramming in distinct cells by let-7. We focus on the participation of the let-7 clusters in immune
cells, and suggest that tissue-specific regulation of the let-7 clusters by engineered mouse models might impact
metabolic homeostasis and will be required to elucidate their physiological and pathological roles in the in vivo
disease models.
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Although initial observations in immune-metabolism were made
nearly a century ago, recent work of cellular metabolism broadly and
deeply permeated immunological research [1,2]. Researches have
been elucidating the molecular basis for how extracellular signals or
molecules control the uptake and utilization of nutrients in quiescent
and activated immune cells [3,4]. Mounting evidences support the
concept that deep understanding how metabolic programs regulates
immune cell functional roles may provide new therapeutic
opportunities for many pathological diseases, which are associated
with dysregulation of immune system, such as type II diabetes (T2D)
[5–7]. Different subtypes of immune cells can adopt distinct
metabolic allocations that allow the immune cells to adjust its
requirements for energy and maintain its physiological functions
[8,9]. The big challenge of immune cell metabolic network has always
been its own complex, which derives from plentiful tiny metabolites
and the complex regulation of the activities of key enzymes as well as
transportations and accumulations of key metabolites.
MicroRNA (miRNA) is a small non-coding RNA that is highly
conserved from worms to humans. It mediates multiple metabolic
activities, depending on its binding capacity to the three prime
untranslated region (3’-UTR) of the targeted mRNAs for repressing
corresponding target gene expression by either translational inhibition
or mRNA decay [10–12,19–21]. The “seed sequence” is essential for
the binding of the miRNA to the mRNA. The seed sequence (also
called seed region) is a conserved short sequence that is mostlysituated at positions 2–7 (or 2–6, or 2–8) from the 5′-end of miRNAs
[13]. Even though base pairing of miRNA and its target mRNA does
not need to match perfectly, the “seed sequence” has to be perfectly
complementary in most cases [14].
Currently, a series of miRNAs have been recognized as biomarkers
in clinical medicine, with high conserved expression across species,
such as miR-155 in breast cancer and acute myeloid leukemia
[15–18]. They also make great contributions to the control of energy
homeostasis and metabolic disorders such as T2D [19–21]. Although
the sophisticated mechanisms of action and the multipronged
influence of miRNAs on physiological and pathological activities
have not been fully interpreted, recent progress has been made in
deciphering the individual roles of certain miRNA such as the let-7
cluster in specific immunological contexts.
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one of the well-studied miRNA clusters [22–24]. The role of let-7
family members as a tumor suppressor has been very well documented
but their physiological roles in the regulation of immune cell
responses is slowly unfolding [24–26]. The dys-regulated expression
of let-7 can lead to aberrant immune function, including the
development of multiple sclerosis and asthma [27,28]. In recent years,
a couple of let-7 family members have implicated in metabolic
reprogramming and immune system development. Let-7’s function
has increased notably, and there has been collected discussion of their
potential use as therapeutics for metabolic-related and immune-
related diseases [29–33].
In this review, we discuss the general features of the let-7 family
across different species, with a brief discussion on its regulation. We
then discuss recent advances in let-7 regulation of physiological and
pathological metabolic reprograms, focusing on current but limited
information regarding the metabolic network and their mechanisms
underlying this regulation in various mouse models in vivo and tissue
cultures in vitro. In the next section, we explore the connection
between dys-regulated let-7 cluster expression and metabolic
regulation in different types of immune cells. With our current
understanding of the functions and mechanisms of let-7, we find thatFigure 1. General features of mature let-7. (A) Chromosome loca
sequence of murine let-7 genes. (C) Sequence comparison of maturthere is great promise in the field for using let-7 both to understand
the metabolic mechanisms of immune cell fate decisions and to
develop diagnostic and therapeutic strategies for aberrant immune
cell-related human diseases.
Let-7 Cluster
Some miRNAs are situated in polycistronic miRNA “clusters”,
wherein majority of miRNA genes are generated only from a single
primary transcript [34,35]. The high conservation of miRNA clusters
across species indicates evolutionary pressure to maintain such a
complicated regulation network. One of the best-characterized
polycistronic miRNA clusters is the let-7 cluster [23]. Forward
genetics experiments initially identified let-7 as a heterochronic gene
in Caenorhabditis elegans (C. elegans) [36–38]. In mice, twelve let-7
genes are present in the murine genome and disperse as eight clusters
on seven different chromosomes, although some of let-7 genes are
clustered together such as the let-7a-1/let-7d/let-7f-1 cluster (let-7adf)
(Figure 1, A–B) [39]. In human, the let-7 family is composed of nine
mature let-7 members, which are encoded by twelve different
genomic loci [33]. Interestingly, the worm and the fly have only single
member, named as cel-let-7 and dmel-let-7, respectively [40]. This
might be because of the unique functional demands for let-7 or anytion and distribution of let-7 genes in murine genome. (B) Mature
e let-7d across species.
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of the driving forces underlying the formation and evolution of single
let-7 miRNA clustering in worm and fly, which needs a mechanism to
deepen our understanding of evolution between genomic contexts
and novel let-7 clusters in higher species, supporting the “functional
co-adaptation” for let-7 miRNA clustering. Further experiments, for
instance, by transfecting cel-let-7 or dmel-let-7 miRNAs into human
or mouse cells and extensively profiling the transcriptome alteration
with deep-sequencing, so it could demonstrate the functional co-
adaptation between lower and higher animal miRNAs in the let-7
clusters. Generally, higher animals have similar sets of let-7 family
members, although slight differences may be observed, for example,
let-7 h (dre-let-7 h) only exists in the zebrafish but not in the human
and mouse genomes [41]. Different from other miRNA clusters, such
as the miRNAs encoded by the miR-17-92 cluster which can be
group into four different “seed” families, whose members are
predicted to target distinct sets of genes, all let-7 members share the
same “seed” [42,43] in mouse and human genome and this seed
region is generally the most critical portion of let-7 functional
elements, suggesting that functional redundancy of let-7 may exist
[23]. Intriguingly, over 50 species including C. elegans, Drosophila,
Zebrafish, Mus musculus and Homo sapiens all express a same version
of let-7d seed sequences (nucleotides 2–8 in mature miRNAs)
“GAGGUA”, but interestingly, only Canis familiaris has its own
version of “UAUACG” (Figure 1C) [23,26]. This conserved feature
of let-7d suggests that its targets and functions may be similar across
diverse animal species. What is the difference between the
bioprocessing of Canis familiaris let-7d from others such as mmu-
let-7d? Is the Canis familiaris let-7d functional different or redundant
in different type of cells, compared with other members? What is the
physiological role of Canis familiaris let-7d in vivo? It is worthy to
address all these questions and understand why Canis familiaris let-7d
is unique in future.
To deep understanding the differences of biological functions
among each let-7 cluster, identification of the miRNA recognizing
element (MRE) is the initial step, because it is well known that
miRNA target recognition is largely dictated by short “seed”
sequences, and binding of miRNAs with their targets is strongly
affected by the nucleotides in the 5′ end of the miRNA–MRE duplex,
however, the flanking sequences (non-seed) around short “seed” also
contribute to specific miRNA–target interactions [51,52]. Despite
the strong similarity in the sequences of let-7 clusters, tiny differences
in their “non-seed” mature sequences may result in both overlapping
and distinct messenger RNA targets. It has been reported that both
the functional partnership between seed and non-seed sequences in
mediating C. elegans temporal development and a diversity among
miRNA effectors in the contributions of seed and non-seed regions to
activity, thus, single point mutations on the non-seed sequences of
each let-7 cluster would help to define the sequence requirements of
let-7 single member or cluster's bio-functions [53–55]. We may thus
hypothesize that advanced technologies such like (CRISPR)/Cas9 or
transcription activator-like effector nuclease (TALEN) may be
utilized to interrogate the functional relevance of non-seed region
of different clusters to post-transcriptional silencing in several species
including C. elegans, Zebrafish and Drosophila. Moreover, investigat-
ing how let-7 miRNA family members are expressed in clusters and
how they control signaling pathways is likely to increase the
knowledge of several biology processes. Let-7 is regulated by key
transcriptional factors such as c-Myc that control the above-mentioned processes as well as RNA-binding proteins including
lin28a/b, which has been reviewed widely [25,48–50]. To further
understanding of the half-life and stability of the pri-let-7, pre-let-7
and mature let-7 would help provide insight into each let-7 cluster's
tissue-specific functions in various immune cells.
This combined mutual repression may therefore accelerate the
understanding of the contribution of specific let-7 member–target
interactions to the regulation of biological processes in vitro and in
vivo. Future work will reveal the mechanisms that determine seed
dependence and non-seed contributions for different let-7 member:
target in distinct cells. It will be interesting to address whether it is
evident that noncanonical let-7–target interactions where no match to
the seed. For instance, Ago-RISC prepared from different immune
cells could be used to understand how the stabilities of miRNAs in
Ago proteins are influenced by non-canonical interactions. The non-
canonical interactions of let-7 and targets may provide a novel means
to fine-tune, refine and diversify miRNAs in different cells. A deeper
understanding of the more precise contributions from interactions
between let-7-mediated seed and/or non-seed with target may provide
new avenues for using accurate let-7 member to alter the function of
specific immune cell subsets.
It is unclear whether and how the multiple let-7 clusters are
functionally equivalent or control different molecular pathways, and
the majority of their functionally relevant targets also remain to be
further identified. The analysis of genetically engineered mice
carrying gain-of-function and loss-of-function mutations of each
let-7 cluster will be essential to furthering our understanding of the
biological functions of this important let-7 cluster.
Let-7 in Physiological and Pathological Cellular Metabolic
Reprogramming
Recent findings reveal that miRNAs also contribute to insulin
signaling and glucose homeostasis and highlight the potential
pathological roles of aberrant miRNA expression in metabolic
disorders such as obesity, insulin resistance (IR), and T2D [56].
Proper control of metabolic homeostasis is crucial to the maintenance
of human health. Global expression analyses demonstrate that
alterations in miRNA levels correlate with various metabolic diseases
[57]. MiRNAs have been showed to regulate central metabolic
pathways and thus play vital roles in maintaining organismal energy
balance and metabolic homeostasis [58]. For example, miR-103/107
regulates insulin and glucose homeostasis [59], whereas miR-34a
regulates hepatic lipid homeostasis [60].
Let-7 was recently shown to be involved in the regulation of
glucose metabolism [31,44,61,62]. The emergence of let-7 as
important regulators of metabolism has gained much interest from
a clinical perspective, and let-7 target genes are associated with T2D
in human a genome-wide association study (GWAS) [62].
Genetically engineered mouse models of let-7 are critical for
evaluating the physiological roles of this miRNA cluster in metabolic
diseases such as obesity and diabetes. For instance, global
overexpression of let-7 g in mice results in growth retardation and
impairs glucose tolerance [30]. Global knockdown of the let-7 family
by anti-let-7 could be sufficient to prevent impaired glucose tolerance
and enhance blood glucose levels and insulin resistance in obese mice
[30]. Mechanistically, anti-let-7 improves insulin sensitivity in both
liver and muscle, at least by partially restoring expression levels of
insulin receptor (INSR) and insulin receptor substrate 2 (IRS2)
(Figure 2, A–D) [30]. Thus, knockdown of let-7 by anti-let-7 may
Figure 2. Regulation of metabolic programs by let-7 in different tissues through targeting single or multiple genes.
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can also regulate glucose metabolism in multiple organs (Figure 2, B
and C) [30]. Specific overexpression of let-7 in skeletal muscle is
sufficient to promote growth [61]. Overexpression of let-7 affects not
only organismal size and onset of puberty in mice but also human
retardation [62]. Pancreas-specific overexpression of let-7 in mice
results in impaired glucose tolerance and reduced glucose-induced
pancreatic insulin secretion [30]. Inducible let-7 transgenic mice not
only have reduced body size and growth retardation, but also have
hyperglycemia and glucose intolerance [31]. The ability to closely
recapitulate human physiology and pathology in mouse models, and
the conservation between humans and mice suggest that studies of let-
7 in mice could provide the most meaningful insights on the role of
this clusters in the molecular pathogenesis of human diseases. Current
evidence of let-7 is also being directed towards the development of
useful mouse models to evaluate these miRNAs therapeutics pre-
clinically. The CRISPR-Cas9 system is capable of producing multiple
miRNA knock-in/out mouse models in few weeks and, therefore, has
immense potential in let-7 clusters functional delineation in multiple
human cellular contexts.
Let-7 is also important to the regulation of metabolic programs in
various cell lines. For example, in mouse embryonic stem cells (ESCs),
inducing let-7 plays a critical role on the Threonine (Thr)-Glycine (Gly)-
S-adenosyl-methionine (SAM) pathway [63]. In mouse embryonic
fibroblasts (MEFs), suppression of let-7 alone is not sufficient to regulate
the regenerative capacity but has no effect on cell migration [32]. In
myoblasts, let-7 regulates Akt and S6 phosphorylation, which enhances
the insulin-sensitivity and glucose uptake [62]. Let-7 is essential to
nutrient homeostasis in higher organisms. In muscle and white fat, let-7
prevents mTORC1 activation to induce autophagy under nutrient
deprivation [29]. In maturing cardiomyocytes (CMs), let-7 is an
important mediator in augmenting metabolic energetics. Let-7 regulates
cardiomyocytes metabolism by promoting maturity of stem cell
derivatives through simultaneously repressing on two of its targets,
IRS2 and EZH2 (Figure 2F) [46]. Let-7 repression by anti-let-7 is
necessary but insufficient to enhance tissue repair, but interestingly,
despite an efficient knockdown of let-7, neither systemic nor topical
delivery of anti-let-7 enhances pinnal tissue repair whereas overexpressionof let-7 after ear punch biopsy inhibits wound closure and pinnal
repair [32].
Metabolism is not only regulated by let-7 in normal tissues but also
in pathological cellular context. For example, let-7 family miRNAs,
most notably let-7 g, repressed aerobic glycolysis in human
hepatocellular carcinoma cancer cell lines (HCCs). Let-7 overexpres-
sion blocks glucose uptake in the examined HCCs, and let-7
specifically suppresses Pyruvate dehydrogenase kinase isozyme 1
(PDK1) expression but no other Oxidative phosphorylation
(OxPhos) enzymes (Figure 2E) [64]. Up-regulation of let-7a
contributes to the attenuation of endothelial cell migration and
insulin signaling induced by acrolein [65]. The circulating levels of
let-7 g display a female-specific elevation in individuals with
metabolic syndrome, which is associated with the risk of developing
cardiovascular disease and T2D [66,67]. Let-7 also contributes to IL-
13 synthesis and release in skeletal muscle from insulin-resistant T2D
patients [68]. Interestingly, let-7 could couple with lin-4, which is
another miRNA that was identified from a study of developmental
timing in the C. elegans, to regulate intestinal mammalian target of
rapamycin (mTOR) signaling so it regulates fat metabolism and
vitellogenesis through the PQM-1 zinc finger transcription factor in
C. elegans [69]. A number of open questions remain concerning the
function of let-7 in metabolic control. For example, it is unclear
whether let-7 has important regulatory impact on cholesterol and
lipid metabolism in vitro and in vivo, and how widespread the
contribution of individual let-7 member is to metabolic control.
Other factors that regulate the expression of let-7 also might indirectly
contribute to metabolic reprograms. For example, miR-107 has been
reported to negatively regulate let-7 through a direct interaction. Deletion
of miR-107 dramatically increases the stability of mature let-7 and down-
regulates let-7 targets because miR-107 directly interacts with let-7
through internal loop of the let-7/miR-107 duplex is critical for repression
of let-7 expression [70]. Does miR-107 affect metabolic programs in vivo
by targeting let-7? The miR-107 iTg and KO mouse models as well as
miR-107/let-7 double transgenic mouse models could be utilized to
address these questions in future.
Different factors including serum, glucose, TNF-α and even
caffeine can regulate the promoter activity and the let-7a-1/let-7d/let-
Figure 3. Regulation of let-7 biogenesis by various factors.
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ylase inhibits glycolytic metabolism by regulating let-7 expression in
neuroblastoma [72]. Acting as a molecular sponge, long noncoding
RNA H19 inhibits let-7 (Figure 3) [73]. Acute hyper-insulinemia can
down-regulate H19 through PI3K/AKT-dependent phosphorylation
of the miRNA processing factor K-homology splicing regulatory
protein (KSRP), which promotes let-7 biogenesis and also mediates
H19 destabilization [74]. Could the influence of let-7 on growth and
metabolism be mediated by any other interacting factors such as H19?
The molecular details of the interaction on this miRNA in metabolic
diseases await further elucidation. Future work should hone in on
comprehensively analyzing the gene regulatory networks mediated by
let-7 clusters that drive aberrant metabolic-related issues as well as
factors controlling let-7 expression, with the aim of identifying key
nodes for targeted therapeutic delivery of let-7 and its related
molecules.Roles of Let-7 in Energy and CellularMetabolism in Immune Cells
In comparison to their well-defined role in tumorigenesis as a
tumor suppressor, let-7 is frequently expressed in a variety of immune
cells, including B cells and macrophages [44,45]. Moreover, the
individual let-7 family member can regulate multiple components of
both normal and disease pathways of metabolism and immune cell
homeostasis [29,44]. The development of some metabolic diseases
such as diabetes involves a complex interaction between pancreatic β-
cells and cells of both the innate and adaptive immune systems
[75,76]. Recently, Immune-metabolism has emerged as a chief
breakthrough especially in the field of diabetes mellitus [77,78]. The
activation, growth, proliferation, and effector functions of different
types of immune cells are intimately linked and dependent on
dynamic changes in cellular metabolic programs [4]. Based on recent
studies, let-7 is mostly linked to activation of B cells, macrophage
responses, and proliferation and activation of T cell lineage
[30,44,46,47].
B cells promote metabolic disease by supporting T cell–mediated
inflammation and insulin resistance and B cell–null mice are
protected from pathogenic outcomes of obesity and inflammation
[79,80]. Upon activation of B cell by toll-like receptor (TLR) ligands,
B cell can further proliferate and differentiate to generate antibody-
producing cells [81]. The metabolic demands are high in the
proliferative early B cell stages in the bone marrow (BM) and lower in
the pre-B, immature, and transitional stages of spleen [82]. After
generation of the mature B cell repertoires, energy needs be uptakeand utilized for antigen-driven proliferation and antibody production
[81]. Glucose, glutamine, and fatty acids are three necessary sources
of nutrients for B cell growth and energy support [83]. Glucose
uptake, which boosts dramatically after B cell activation, provides the
substrate for glycolysis and pyruvate molecules for TCA cycle entry
[84]. Uptake and utilization of glutamine also increases dramatically
after B cell activation, followed by the induction of increased solute
transporter proteins and is up-regulated in a manner dependent on
PDK1 and AKT [85,86]. Importantly, glutamine provides another
potential source of nitrogen and enters mitochondria and feeds the
TCA cycle after anaplerotic conversion into a-ketoglutarate (a-KG)
through glutaminase (Gls)-mediated generation of glutamate [87]. In
TLR4 agonist-activated B cells, analogous mTORC1-dependent
increases in amino acid uptake and mTORC1 activation have been
noted [88]. C-Myc, which is a canonical target of let-7 [89], is a
master regulator of cell proliferation and growth [90,91], and it
promotes transcription and translation of key effectors in response to
nutrient uptake and mTOR activation [92]. Our recent work shows
that let-7adf specifically inhibits T cell-independent (TI) antigen-
induced IgM antibody production and we find this miRNA cluster
suppresses the acquisition and utilization of both glucose and
glutamine, through directly targeting hexokinase 2 (Hk2) and
repressing a glutamine transporter Slc1a5 and Gls, a mechanism
mediated by regulation of c-Myc (Figure 4A). This study suggests a
novel role of let-7adf as a “metabolic brake” on B cell antibody
production [44]. Although it is clear that the let-7adf cluster acts as a
negative regulator of TI-induced antibody production, a deeper
understanding of whether and how let-7 clusters regulate metabolic
phenotypes to support B cell functions, such as CSR and memory
responses, and will shed light on how let-7 adapts to different
physiological environments. In addition, further understanding the
let-7adf cluster's pathological role in B cells requires long-term
monitoring of aging let-7adf KO mice or using the pathological
mouse models such as systemic lupus erythematosus (SLE) model.
The potential for mechanistic links between intracellular metabolites
to effect changes in the posttranscriptional networks mediated by
miRNAs such as let-7 needs to be elucidated as well in future.
In the case of regulating B cell metabolism, the body of work with
B cells is as yet far less extensive investigated than that with T cells or
macrophages. For example, macrophages fulfill a broad range of
functions in host defense, tissue homeostasis and pathology [93,94].
Recently, a growing number of studies highlight the crucial role of
metabolic reprogramming in macrophage activation [95,96]. Meta-
bolic pathways not only provide energy but also regulate the
macrophage's phenotype and functions. While the induction of
glycolysis is well accepted as a key feature of inflammatory
macrophages (M1 macrophages), the mechanisms linking metabolic
rewiring and macrophage function remained largely obscure.
Literature elegantly demonstrates how particular glycolytic enzymes
support pro-inflammatory macrophage functions [97,98]. Succinate,
a TCA cycle intermediate, is a critical metabolite that modulates
macrophage inflammatory responses by enhancing expression of the
key pro-inflammatory cytokine, IL-1β [99,100]. Our recent work
shows that using both KO and myeloid cell-specific transgenic mouse
models, we find that a physiological role of the let-7adf cluster is to
promote IL-6 secretion by LPS-activated macrophages through
down-regulating Tet2 (Figure 4B). This let-7 cluster represses Tet2
using two different mechanisms: direct targeting and indirect
enhancement of succinate accumulation. A further understanding
Figure 4. Let-7 plays critical roles in different types of immune cells.
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macrophage activation, such as M2 macrophage responses and
monocytes differentiation, and will shed light on how let-7 adapts to
different innate immune systems.
Lately, endogenous metabolites including itaconate and succinate
have emerged as key regulators of macrophage function [100,101],
but their precise regulatory mechanism of action remains unclear.
Although the let-7adf cluster is critical regulator of macrophage
inflammatory responses, whether and how they are involved in M1
macrophages needs to be further understood. In addition, it may be
possible to target metabolic changes in macrophages therapeutically
through anti-let-7. Moreover, approaches might include inhibition of
isocitrate dehydrogenase (IDH) and/or SDH, which will prevent
inflammatory macrophage activation while supporting anti-
inflammatory pathways, including the induction of IL-10 and
suppression of IL-1β. Further work will be needed to explore the
utility of targeting specific metabolic events in macrophages for
therapeutic gain and anti-let-7 treatment might have good potential.
CD4 T cells can respond to T cell receptor (TCR) signaling with
full activation and the acquisition of effector functions [102]. Anergy
CD4 T cells display the inability to proliferate and effector functions
including cytokine secretion in response to secondary stimulation
[103]. Profiling analysis of TCR-induced signaling showed elevated
phosphorylation of AKT S473 and S6 ribosomal protein [104],
indicating hyperactivity of mTORC1 and mTORC2 and overex-
pression of the key mTOR complex components Raptor and Rictor
[105]. It has been reported that let-7c-mediated regulation ofmTORC2 can facilitate discrimination between activation and anergy
in CD4 T cells (Figure 4C) [106]. CD8 T cells undergo rapid clonal
expansion after antigen recognition, followed by differentiation into
effector cytotoxic T lymphocytes (CTLs) and memory T cells, which
are both capable of producing effector cytokines and eliminate target
cells [107]. This transition in CD8 T cells is accompanied with
metabolic reprograming from oxidative phosphorylation to aerobic
glycolysis, providing energy and larger amounts of the biomacromo-
lecular intermediates needed to support growth [108]. Let-7 g acts as
a molecular hub by converting the strength of TCR signaling into
CD8 T cell function and it suppress the proliferation and metabolism
of activated CD8 T cells through the suppression of c-Myc, and
repression of effector function through both eomesodermin (Eomes)-
dependent and -independent mechanisms (Figure 4D) [47]. It is
interesting to investigate whether let-7 is involved in other T cell
subtypes such as Th1 and Th17 cells. The T cell conditional KO or
iTg mouse models might be utilized to answer these questions.
Regarding the influence of let-7 on the complex crosstalk among T
cells, B cells, and macrophages, there have been no studies
demonstrating this role in the pathological disease models such as
murine systemic lupus erythematosus (SLE) model. In thinking of
these similar clusters, however, it is important to consider that single
or multiple clusters may be involved in regulating a single mRNA
target that may be involved in regulating immune cell functions. It is
now well recognized that let-7 controls metabolism in several
subtypes of immune cells, thereby generating a functional link, which
disrupts energy homeostasis in case of disconnection in the miRNA-
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role of let-7 cluster in other subtypes of immune cells such as dendritic
cells (DCs) and regulatory T cells (Treg) cells, which play important roles
in the pathogenesis of diseases such as T2D and for establishing their
usefulness as new medications and clinically reliable biomarkers.Current Opinion and Future Conceptual Perspective on Let-7
Despite great progress in understanding the let-7 cluster's roles in
metabolic programming in different types of cells including immune
cells, several key questions remain unanswered. Let-7 functions as
efficient fine-tuners of protein expression, rather than as “on–off”
switches and they represent a mechanism to balance the immune cell
responses, which when left unchecked, can have physiological or
pathological effects. Future studies should also be undertaken to find
out whether other factors are utilized in most tissues to modulate
expression of let-7 in various immune cells. Given the importance of
let-7 in processes such as inflammation, and antibody production and
understanding of these precisely controllers may translate in
therapeutic strategies to treat human diseases.
A central issue regarding let-7 concerns the assessment of let-7 activity
and function, both of which depend on which let-7 cluster or member
functions and on the relative let-7 targets. When considering the
therapeutic potential of let-7, it must be kept in mind that the factors
influencing biological roles of let-7 should also be considered by its own
concentration, in addition to its multiple targets. Certain mature let-7
might regulate the expression of bioprocessing of its own or other let-7
clusters in the cytoplasm, where they function in a noncanonical manner
by directly regulating Dicer [109]. Extracellular let-7 are indeed involved
in cell–cell communications, for instance, exosome-mediated transfer of
let-7d from Treg cell to Th1 cells contributed to suppression and
prevention of systemic disease, which would show promise for their use as
potential therapeutic tools [110,111]. Exosomes are predicted to have low
antigenicity and toxicity, thus it is extremely important as carriers for
targeted delivery of let-7. Such a novel experimental tool would reveal
their possible utility in the treatment of diseases or as targets of therapeutic
interventions. In addition, the possible clinical roles that let-7 might play
in immune pathology could be understood by using engineered let-7
clustermousemodels. A very important question is that of identifying and
validating the let-7 cluster's targetome in different types of immune cells,
which is critical for our understanding of the regulatory networks
governing biological processes mediated by let-7. It is also important to
note that an increased number of validated target set might open up new
avenues for therapeutic intervention in those settings, where one or more
of the cluster's members are involved. Comparing different mechanisms
by which individual let-7 cluster affects the immune system will be
required to elucidate their roles in the in vivo disease models. Mouse
diseasemodels in vivowould shed light on the potentiality of targeting let-
7 components therapeutically.
Although the use of intravenous delivery of anti-let-7 for the tumor
treatment in immune-compromised mice has showed effective role in
blockage of tumor growth, indicating let-7 as a potential therapeutic
target [112–115], there are still some issues need to be addressed, for
instance, the selective delivery such as the blood–brain barrier (BBB)
and side effects. Further studies are necessary to assess the impact of
specific let-7 cluster-mediated therapies for prevention of off-target
effects and improvement of delivery efficiency while preventing
inflammatory responses. Additionally, elucidating the individual
functions of let-7 clusters towards different physiological roles will befundamental to understand the degree of functional overlap and
interworking among all these miRNA let-7 clusters.
Given the importance of let-7 in regulating metabolism, it is
tempting to speculate that at least one let-7 cluster might play a role in
modulating metabolism in each cellular context. The generation of
engineered mouse models to study each individual let-7 member is
warranted to fully answer these essential questions, which we trust
will provide new insights into the regulation of crucial metabolic
programs by let-7 and indicate an additional level of regulation by this
conserved class of RNA molecules in the form of functional overlap.
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